| 1.18 0.05 (4.42%) | 04-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.86 | 1-year : | 2.2 |
| Resists | First : | 1.59 | Second : | 1.88 |
| Pivot price | 1.32  |
|||
| Supports | First : | 1.12 | Second : | 0.93 |
| MAs | MA(5) : | 1.17 |
MA(20) : | 1.4 |
| MA(100) : | 1.73 |
MA(250) : | 1.34 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 7.9 |
D(3) : | 8.7 |
| RSI | RSI(14): 36.1 |
|||
| 52-week | High : | 2.65 | Low : | 0.33 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TOI ] has closed above bottom band by 26.3%. Bollinger Bands are 2.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.22 - 1.23 | 1.23 - 1.23 |
| Low: | 1.12 - 1.12 | 1.12 - 1.13 |
| Close: | 1.17 - 1.18 | 1.18 - 1.19 |
The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. The company operates 67 clinic locations. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California.
Tue, 23 Apr 2024
The Oncology Institute Announces First Quarter 2024 Earnings Release Date and Conference Call - Yahoo Finance
Sat, 06 Apr 2024
The Oncology Institute, Inc. (NASDAQ:TOI) Shares Acquired by Kent Lake Capital LLC - MarketBeat
Thu, 04 Apr 2024
The Oncology Institute and Healthly Forge Strategic Alliance to Elevate Cancer Care Access to Healthly Patients ... - GlobeNewswire
Wed, 27 Mar 2024
The Oncology Institute Reports Fourth Quarter and Full Year 2023 Financial Results and Guidance for 2024 - GlobeNewswire
Wed, 27 Mar 2024
The Oncology Institute Inc (TOI) Reports Mixed Q4 and Full Year 2023 Results - Yahoo Finance
Wed, 27 Mar 2024
TOI Stock Earnings: The Oncology Institute Misses EPS, Beats Revenue for Q4 2023 - InvestorPlace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Care Facilities
|
|
| Shares Out | 74 (M) |
| Shares Float | 33 (M) |
| Held by Insiders | 19.7 (%) |
| Held by Institutions | 57.5 (%) |
| Shares Short | 263 (K) |
| Shares Short P.Month | 226 (K) |
| EPS | -0.93 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.76 |
| Profit Margin | -25.7 % |
| Operating Margin | -18 % |
| Return on Assets (ttm) | -16 % |
| Return on Equity (ttm) | -92.2 % |
| Qtrly Rev. Growth | 20.1 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 4.36 |
| EBITDA (p.s.) | -0.74 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -36 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | -1.29 |
| PEG Ratio | 0 |
| Price to Book value | 1.53 |
| Price to Sales | 0.27 |
| Price to Cash Flow | -2.42 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|